Trial Profile
Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, in Patients With Progressive and/or Refractory Hematologic Malignancies
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs KiroVAX 002 (Primary) ; KiroVAX 002 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Kiromic
- 24 Aug 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 05 Jun 2018 Trial design of NCT02709993; NCT02705703; NCT02224599 and NCT02223312 studies, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Aug 2017 Planned End Date changed from 1 Sep 2017 to 31 Jan 2019.